过去一年中添加的文章，按日期排序

Off-target autophagy inhibition by SHP2 allosteric inhibitors contributes to their anti-tumor activity in RAS-driven cancers

Y Miao, Y Bai, J Miao, AA Murray, J Lin… - The Journal of …, 2024 - Am Soc Clin Investig
59 天前 - … that SHP2 allosteric inhibitors harboring this off-target activity not only suppress
oncogenic RAS signaling but also overcome drug resistance … of SHP2 allosteric inhibitors for …
相关文章 所有 3 个版本

Interrogating therapeutic resistance to oncogenic KRASG12C-based therapies in colorectal cancer

O Coker - 2024 - digitalcommons.library.tmc.edu
96 天前 - … the mechanisms of adaptive and acquired resistance, we have … of SHP2 as a
mechanism of adaptive resistance and investigate the efficacy of a KRASG12C and SHP2 inhibitor …
相关文章

Off-target autophagy inhibition by SHP2 allosteric inhibitors and therapeutic implications for aberrant RAS-driven cancers

Y Miao, Y Bai, J Miao, AA Murray, J Lin, J Dong, Z Qu… - Cancer Research, 2024 - AACR
135 天前 - … inhibition by SHP2 allosteric inhibitors contributes to their anti-tumor activity. We
also demonstrated that SHP2 allosteric inhibitors … but also overcome drug resistance such as …
相关文章

JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers

X Lu, R Yu, Z Li, M Yang, J Dai, M Liu - Cancer Letters, 2024 - Elsevier
235 天前 - … Importantly, JC-010a abolished acquired resistance … adaptive resistance mediated
by RTK/SHP2; in BCR-ABL-driven leukemia cells, we demonstrated JC-010a inhibited BCR-…
被引用次数：1 相关文章 所有 2 个版本

Abstract B080: Non-genetic determinants driving sub-clonal resistance to KRAS G12C combination therapies in KRAS mutant non-small cell lung cancer

C Li, CJ Graser, Q Qin, UM Syed, B Karakyriakou… - Molecular Cancer …, 2023 - AACR
247 天前 - … ) feedback reactivation including EGFR, SHP2, and WT RAS … and contributing to
adaptive resistance to KRAS G12Ci … observed that pre-existing resistant clones to KRAS G12Ci …
相关文章

Abstract C141: Targeting SHP2-dependent adaptive resistance to BRAF and MEK inhibition in gliomas

AA Ayanlaja, K Lalwani, M Ioannou, C Pratilas… - Molecular Cancer …, 2023 - AACR
247 天前 - … of resistance that are likely to involve kinome re-programming, treatment-emergent
resistance mutations, and adaptive resistance… Based on the critical role of SHP2 upstream of …
相关文章

Abstract A096: RAS mutation status predicts activity of the SHP2 inhibitor TNO155 in RAS-pathway driven fusion-negative rhabdomyosarcoma

A Baker, P Odeniyide, A Skaist, A Lisok, E Fertig… - Molecular Cancer …, 2023 - AACR
247 天前 - … for adaptive resistance, and combination treatment involving TNO155 and FGFR
or PI3K inhibitors may reduce tumor growth with better efficacy than either compound alone. …
相关文章

Abstract B029: Investigating therapeutic strategies to promote immune rejection of KRAS G12C inhibitor-resistant sub-populations in lung cancer

M Tomaschko, M Molina-Arcas, C Moore, S Rana… - Cancer Immunology …, 2023 - AACR
247 天前 - … drives therapy resistance by giving the drug-resistant … or a SHP2 inhibitor potentiated
an adaptive immune … immune memory towards drug-resistant KRAS G12D cells in mice. …
相关文章
[PDF] aacrjournals.org

SHP2 inhibition with TNO155 increases efficacy and overcomes resistance of ALK inhibitors in neuroblastoma

I Valencia-Sama, L Kee, G Christopher, M Ohh… - Cancer Research …, 2023 - AACR
248 天前 - … Recently, SHP2 inhibitors have been shown to overcome ALK-TKI resistance in
lung … Here, we have assessed the efficacy of the SHP2 inhibitor TNO155 alone and in …
相关文章 所有 6 个版本
[PDF] postersessiononline.eu

SHP2 Inhibition Overcomes Adaptive and Acquired Resistance to FLT3 TKI to Improve Efficacy Against FLT3/ITD AML

T Seale, L Li, JK Bruner, B Nguyen, MJ Levis… - Blood, 2023 - Elsevier
250 天前 - … In addition to rapid adaptive resistance, there are mechanisms of acquired resistance
… We next examined the effects of SHP2 inhibition on FLT3-TKI resistant cells models that …
相关文章 所有 3 个版本